Abstract
The objective of the work was to study PIK3CA mutations in wild type KRAS and BRAF colorectal cancer. Clinicopathological data and paraffin-embedded specimens were collected on 73 patients who underwent colorectal resections at General Yagüe Hospital in Burgos. KRAS, BRAF and PIK3CA status were analyzed by real-time PCR in all patients. PIK3CA mutations were present in 8.22% of wild type KRAS and BRAF colorectal cancers. The most frequent mutation is E545K/D in exon 9 which represents 83.3% of all mutations. By contrast, we did not found any tumour harbouring H1047R mutation in exon 20. Among the patients who undergo a curative resection of colorectal cancer, PIK3CA mutation is present in an important percentage of KRAS and BRAF wild type tumours. PIK3CA mutation may be considered as it could be a hypothetic reason to be not responder to anti-EGFR antibodies.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal, Humanized
-
Cetuximab
-
Class I Phosphatidylinositol 3-Kinases
-
Cohort Studies
-
Colorectal Neoplasms / ethnology*
-
Colorectal Neoplasms / genetics*
-
ErbB Receptors / antagonists & inhibitors
-
Female
-
Humans
-
Male
-
Middle Aged
-
Mutation*
-
Phosphatidylinositol 3-Kinases / genetics*
-
Proto-Oncogene Proteins / genetics*
-
Proto-Oncogene Proteins B-raf / genetics*
-
Proto-Oncogene Proteins p21(ras)
-
Retrospective Studies
-
Spain
-
ras Proteins / genetics*
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
KRAS protein, human
-
Proto-Oncogene Proteins
-
Phosphatidylinositol 3-Kinases
-
Class I Phosphatidylinositol 3-Kinases
-
PIK3CA protein, human
-
ErbB Receptors
-
BRAF protein, human
-
Proto-Oncogene Proteins B-raf
-
Proto-Oncogene Proteins p21(ras)
-
ras Proteins
-
Cetuximab